 |
 |
|
 |
||
Print 
Download Reader 
|
|
|
|
||
Print Download Reader
 |
|
|
National Vaccine Program Office
|
Proposal Number: | C12 |
PI Name: | Schrag, Stephanie |
PI Email: | |
PI Title: | Epidemiologist |
Project Title: | Group B streptococcal vaccine development: Characterization of invasive disease strains. |
Project Start: | 2002 |
Project End: | 2004 |
Abstract: Vaccines to prevent group B streptococcal (GBS) disease hold promise to prevent a broad spectrum of severe disease--pregnancy-associated infections, early and late-onset neonatal infections, and invasive disease in the elderly. Moreover vaccines can alleviate growing problems of emerging antimicrobial resistance.
The objective of the research project is to guide vaccine formulation by characterizing serotype distribution and antimicrobial susceptibility of invasive GBS isolates collected from pregnant women, newborns and adults with invasive disease. The study focuses on residents of the Active Bacterial Core Surveillance/Emerging Infections Program Network (ABCs). Isolates will be collected prospectively from all invasive GBS cases identified in selected counties of six surveillance areas: Colorado, Georgia, Minnesota, New York, Oregon, and Maryland. The isolates will be serotyped and tested for susceptibility at one of two reference laboratories.
This is year 2 of the project. The two years combined are anticipated to provide a sufficient sample size of isolates to characterize serotype and susceptibility distributions that will help guide and motivate research focused on development and phase III testing of GBS conjugate vaccine formulations. Additionally these data characterize the prevalence of resistance and risk factors for resistant invasive GBS disease. New GBS prevention guidelines in 2002 recommended new prophylactic agents for women with severe penicillin allergy and monitoring for the emergence of resistance to these agents is of particular importance. The testing will also provide information on the relationship between resistance and serotype. This may have important implications for vaccine development, particularly if the majority of resistant strains are clustered within a few serotypes.
Institution: Centers for Disease Control and Prevention
Date: July 2003
Last revised: January 13, 2004
|
